期刊文献+

人肿瘤抑素基因真核表达载体的构建及其活性研究

Study on the construction of recombinant AAV vector mediated tumstatin gene and its activity
原文传递
导出
摘要 目的构建携带人肿瘤抑素(Tumstatin)基因的重组腺相关病毒载体,研究其对人脐静脉内皮细胞(HUVECs)增殖的影响。方法构建重组载体pAAV—Tum质粒,并建立一株稳定表达Tumstatin基因的HU—VECs细胞株。用逆转录聚合酶链反应检测该细胞系中Tumstatin基因的表达,四甲基唑蓝法检测该细胞增殖情况。结果构建的pAAV—Turn重组腺相关病毒载体能在HUVECs细胞中表达,其表达产物能抑制该细胞增殖(0.335±0.011)。结论成功构建了pAAV—Turn重组载体,构建的重组载体能有效表达,为其后的抗肿瘤血管生成治疗研究奠定了基础。 Objective To construct the recombinant adeno-associated virus(rAAV)vector containing tumstatin gene and to detect its effect on the proliferation ability of HUVECs cells.Methods The pAAV Turn recombinant plasmid was obtained,and HUVECs cell line stably expressing Tumstatin gene Was established.Then the mRNA level of pAAV Turn was detected by RT-PCR and the proliferation ability of transfected cell line was measured by MTTassay.Results The pAAV Turn recombinant plasmid could express in HUVECs cell and its expression product could suppress the proliferation of HUVECs cell.Conclusion Recombinant AAV vector,which contained Tumstatin gene,was constructed successfully,and can express efficiently.
出处 《长沙医学院学报》 2014年第1期20-22,8,共4页 Journal of Changsha Medical University
基金 湖南省敦育厅基金资助项目(09C153)
关键词 肿瘤抑素 腺相关病毒 基因治疗 tumstatin adeno-associated virus gene therapy
  • 相关文献

参考文献4

二级参考文献17

  • 1黄煌,黄英,易成.肿瘤抑素:一种内源性的肿瘤血管生成抑制因子[J].华西医学,2007,22(4):941-942. 被引量:6
  • 2王淑静,刘岩,林雪松,付雪,徐建永,刘兴汉.肿瘤抑素抗肿瘤相关肽的克隆及生物活性[J].中国生物化学与分子生物学报,2005,21(3):322-328. 被引量:6
  • 3Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangioge- nie therapy: microvessel density, what it does and doesn't tell us[J ]. J Nad Cancer Inst, 2002,94(12) : 883 - 893.
  • 4Harnano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen Ⅳ alpha 3 chain , are generated by MMP - 9 proteolysis and suppress angiogenesis via alpha V beta 3 in- tegrin[J]. Cancer Cell, 2003,3(6) :589 - 601.
  • 5Boosani CS, Mannam AP, Cosgrove D, et al. Regulation of COX - 2 mediated signaling by { alpha } 3 type Ⅳ noncollagenous domain in tu- mor angiogenesis[ J ]. Blood,2007,110(4) : 1 t68 - 77.
  • 6Gafni Y, Pelled G, Zilberman Y, et al. Gene therapy platform for bone regeneration using an exngenously regulated, AAV - 2 - based gene ex- pression system[J]. Mol Ther, 2004, 9(4): 587-59.
  • 7Lipshutz GS, Titre D, Brindle M. Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero[J ]. Mol Ther, 2003, 8(1): 90-98.
  • 8Maeshima Y,Colorado PC,Kalluri R.Two RGD-independent alpha v beta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties[J].J Biol Chem,2000,275(31):23745-23750.
  • 9Maeshima Y,Colorado PC,Torre A,et al.Distinct antitumor properties of a type Ⅳ collagen domain derived from basement membrane[J].J Biol Chem,2000,275(28):21340-21348.
  • 10Petitclerc E,Boutaud A,Prestayko A,et al.New functions for non-collagenons domains of human collagen type Ⅳ.Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo[J].J Biol Chem,2000,275(11):8051-8061.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部